Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis

Revista do Colégio Brasileiro de Cirurgiões
Cláudio Franco do Amaral KfouriJurandyr Moreira de Andrade

Abstract

to analyze the expression of Vascular Endothelial Growth Factor (VEGF), its receptor (VEGFR-2), age and histological type of advanced cervical carcinomas with respect to the clinical response to neoadjuvant chemotherapy. we studied 40 patients with cervical carcinoma (IB2 and IVA) diagnosed by biopsies prior to treatment. All patients underwent neoadjuvant chemotherapy and evaluation for clinical response and expression of VEGF. We considered a tumor regression greater than 50% as a good clinical response. eighteen patients (45%) had good response to chemotherapy, and 22 (55%), poor response. VEGF expression was positive in 16 patients and negative in 24. When analyzed separately for response to chemotherapy, only the positive expression of VEGF was associated with good clinical response (p=0.0157). VEGF expression alone was an important marker of good response to neoadjuvant chemotherapy in patients with advanced carcinoma of the cervix.

References

Feb 20, 1997·International Journal of Cancer. Journal International Du Cancer·M VolmJ Mattern
Feb 28, 1998·Gynecologic Oncology·K TokumoT Kudo
Mar 21, 1998·American Journal of Obstetrics and Gynecology·A ObermairG Gitsch
Jun 2, 1998·Cancer Treatment Reviews·S PignataS Monfardini
Aug 17, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J KodamaT Kudo
Aug 19, 1999·The Journal of Pathology·J M WalboomersN Muñoz
Sep 12, 2001·The Surgical Clinics of North America·J E Sardi

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.